Madrigal Pharma (MDGL) Misses Q3 EPS by 311c

Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($5.08), $3.11 worse than the analyst estimate of ($1.97). Revenue for the quarter came in at $287.27 million versus the consensus estimate of $244.42 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) call put ratio 4.6 calls to 1 put with a focus on with a focus on September 4 weekly 24.50 calls as share price up 2.7%
• Norwegian Cruise Line (NCLH) call put ratio 1.8 calls to 1 put with a focus on a spreader of October and December 19 puts
• Southwest Airlines plans first airport lounges, targeting late 2027